Navigation Links
Brachytherapy For Breast Cancer Can Be Risky

A new study published in the June 2006 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO, the American Society //for Therapeutic Radiology and Oncology, says that doctors in New England have found that patients receiving partial radiation for the breast in order to combat breast cancer have the risk of developing a seroma.

A seroma is retention of fluid in the breast, which can complicate matters since it requires aspiration. The study followed 38 women who had the procedure after undergoing lumpectomy surgery to remove the cancer. After the surgery, a balloon brachytherapy method is used to place a balloon in the space occupied by the tumor.

Radiation Oncologists then deliver high doses of radiation locally in order to kill off any remaining cancer cells. In the current study 76.3 percent of them developed seroma in their breast and 68.4 percent of the patients had it for over 6 months.

'Seroma is not infrequent after surgery, but it typically resolves itself within a few weeks. However, with these patients, the seroma didn’t resolve,' said Suzanne B. Evans, M.D., M.P.H., lead author of the study and a radiation oncology resident at Tufts-New England Medical Center. 'We look forward to other studies in which the device is placed post-operatively to determine whether this lowers the rate of seroma formation.'


'"/>




Page: 1

Related medicine news :

1. Brachytherapy for breast cancer
2. Brachytherapy Shows Promise for Cancer Treatment
3. Prostate Brachytherapy Causes Fewer Side Effects Than Surgery
4. Consensus on "Combination Therapy" for Breast Cancer
5. Breast cancer treatment to be determined by gene test
6. Breast Feeding prevents obesity later on in life
7. Breast milk is essential
8. Breast Cancer Surgery Causes Psychological problems
9. Breast cancer evidence
10. Letrozole Beats Tamoxifen in Breast Cancer Therapy
11. Breast screening among diabetic women
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... , ... International Protein, a company based out of Australia that focuses on ... ECRM trade show in Hilton Head, SC. , International Protein was founded by ... line of products that would elevate her fitness regime. At this ECRM trade show, ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Mary Magdalene: Grace ... mysterious life of the woman who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is ... who spent her career as an educator interacting with countless women who had little ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in a study ... Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Land ... brings attention to the issue of world hunger, and shares the simple and achievable ... Brubaker, devoted husband and member of the Fairview Missionary Church in Angola, Indiana where ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 The U.S. Food and ... Chronic Idiopathic Constipation (CIC) in adult patients. ... gastrointestinal disorders," said Julie Beitz , M.D., director of ... for Drug Evaluation and Research. "With the availability of new ... treatment for their condition." ...
(Date:1/19/2017)... YORK , Jan. 19, 2017 This ... the current and future scenario of the global market. ... rising opioid consumption. Severe chronic constipation is a major ... to traditional laxatives. Hence, novel targeted therapy has been ... OIC sufferers, launch of targeted medicines, and growing awareness ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
Breaking Medicine Technology: